|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-29 | GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment | MT |
| 07-29 | GSK : DZ Bank remains Neutral | ZD |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.55% | 0.61% | 36.25x | 22.14x | 12.94x | 27.18x | 28.26x | 1,089B | ||
| 2.01% | 2.11% | 28.59x | 7.26x | 6.53x | 18.09x | 19.65x | 643B | ||
| 2.61% | 2.75% | 33.13x | 13101.05x | 7.75x | 15.94x | 16.46x | 465B | ||
| 2.72% | 2.78% | 20.2x | 7.34x | 4.86x | 12.04x | 13.44x | 359B | ||
| 2.74% | 2.86% | 22.65x | 6.38x | 5.84x | 14.57x | 15.45x | 303B | ||
| 1.93% | 2.05% | 22.03x | 4.96x | 4.53x | 12.8x | 13.62x | 267B | ||
| 3.38% | 3.3% | 14.79x | 6.53x | 5.48x | 11.3x | 13.29x | 226B | ||
| 2.57% | 2.71% | 25.81x | 19.83x | 6.73x | 11.86x | 15.39x | 212B | ||
| 2.45% | 2.54% | -48.4x | 8.49x | 5.8x | 32.01x | 63.66x | 167B | ||
| 6.82% | 6.88% | 12.82x | 1.64x | 3.13x | 7.91x | 8.94x | 144B | ||
| 3.96% | 4.04% | 12.34x | 5.58x | 3.35x | 9.02x | 9.65x | 130B | ||
| -.--% | -.--% | 27.96x | 5.62x | 8.49x | 19.12x | 20.04x | 124B | ||
| 5.36% | 5.67% | 11.94x | 1.27x | 2.23x | 7.16x | 8.15x | 109B | ||
| 1.96% | 2.24% | 22.69x | 5.13x | 7.63x | 14.47x | 15.15x | 70.35B | ||
| 3.56% | 3.64% | 47.41x | 1.22x | 2.82x | 9.99x | 29x | 56.03B | ||
| 0.48% | 1.34% | 20.33x | 1.65x | 1.71x | 8.12x | 13.64x | 52.65B | ||
| 0.5% | 0.56% | 38.22x | 5.11x | 8.63x | 28.63x | 29.94x | 51.98B | ||
| 2.1% | 2.33% | 19.67x | 1.98x | 3.55x | 13.32x | 14.96x | 44.64B | ||
| -.--% | -.--% | 37.92x | 18.11x | 6.35x | 28.88x | 27.91x | 38.51B | ||
| Average | 2.41% | 2.55% | 21.39x | 696.38x | 5.70x | 15.92x | 19.82x | 239.59B | |
| Weighted average by Cap. | 2.13% | 2.23% | 24.58x | 1,348.20x | 7.49x | 17.99x | 20.59x |
- Stock Market
- Stocks
- GSK Stock
- Stock
- Sector GlaxoSmithKline plc
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
















